Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability.
نویسندگان
چکیده
OBJECTIVE/BACKGROUND The National Institute of Mental Health (NIMH) Research Units on Pediatric Psychopharmacology (RUPP) Autism Network found an effect size of d = 1.2 in favor of risperidone on the main outcome measure in an 8-week double-blind, placebo-controlled trial for irritability in autistic disorder. This paper explores moderators and mediators of this effect. METHOD Intention-to-treat (ITT) analyses were conducted with suspected moderators and mediators entered into the regression equations. MacArthur Foundation Network subgroup guidelines were followed in the evaluation of the results. RESULTS Only baseline severity moderated treatment response: Higher severity showed greater improvement for risperidone but not for placebo. Weight gain mediated treatment response negatively: those who gained more weight improved less with risperidone and more with placebo. Compliance correlated with outcome for risperidone but not placebo. Higher dose correlated with worse outcome for placebo, but not risperidone. Of nonspecific predictors, parent education, family income, and low baseline prolactin positively predicted outcome; anxiety, bipolar symptoms, oppositional-defiant symptoms, stereotypy, and hyperactivity negatively predicted outcome. Risperidone moderated the effect of change in 5'-nucleotidase, a marker of zinc status, for which decrease was associated with improvement only with risperidone, not with placebo. CONCLUSION The benefit-risk ratio of risperidone is better with greater symptom severity. Risperidone can be individually titrated to optimal dosage for excellent response in the majority of children. Weight gain is not necessary for risperidone benefit and may even detract from it. Socioeconomic advantage, low prolactin, and absence of co-morbid problems nonspecifically predict better outcome. Mineral interactions with risperidone deserve further study.
منابع مشابه
Comparative Study on the Effect of Risperidone and its Combination with Naltrexone in Pediatric Patients with Autistic Spectrum Disorders: A Clinical Trial Study
Background Autistic spectrum disorder (ASD) refers to a syndrome associated with persistent impairments in communication skills, social interactions, and so forth. Given the approval of risperidone and naltrexone by U.S. Food and Drug Administration (FDA) for ASD cases and extant controversy concerning their pertained side effects, this double-blind, placebo-controlled, crossover clinical trial...
متن کاملEfficacy and Safety of Aripiprazole for Treatment of Irritability in Children with Autistic Disorder: An Open-Label Study
متن کامل
Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Irritability in Autistic Children
Children with autism have a high rate of irritability and aggressive symptoms. Irritability or self-injurious behavior can result in significant harm to those affected, as well as to marked distress for their families. This paper provides a literature review regarding the efficacy and tolerability of pharmacotherapy for the treatment of irritability in autistic children. Although antipsychotics...
متن کاملRisperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months.
OBJECTIVE Risperidone is effective for short-term treatment of aggression, temper outbursts, and self-injurious behavior in children with autism. Because these behaviors may be chronic, there is a need to establish the efficacy and safety of longer-term treatment with this agent. METHOD The authors conducted a multisite, two-part study of risperidone in children ages 5 to 17 years with autism...
متن کاملThese highlights do not include all the information needed to use Risperidone safely and effectively. see full prescribing information for Risperidone. Risperidone (Risperidone) SOLUTION for ORAL use. Initial U.S. Approval: 1993
INDICATIONS AND USAGE Risperidone oral solution, USP is an atypical antipsychotic agent indicated for: (1) Treatment of schizophrenia in adults and adolescents aged 13 to 17 years (1.1) Alone, or in combination with lithium or valproate , for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults, and alone in children and adolescents aged 10 to 1...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Journal of child and adolescent psychopharmacology
دوره 20 2 شماره
صفحات -
تاریخ انتشار 2010